Rivian Automotive (RIVN) Gets a Hold from Mizuho Securities
Mizuho Securities analyst Vijay Rakesh reiterated a Hold rating on Rivian Automotive (RIVN – Research Report) today and set a price target of $13.00. The company's shares closed today at $13.91.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Rakesh is a 5-star analyst with an average return of 15.9% and a 55.00% success rate. Rakesh covers the Technology sector, focusing on stocks such as Credo Technology Group Holding Ltd, Broadcom, and Nvidia.
Currently, the analyst consensus on Rivian Automotive is a Hold with an average price target of $14.61, a 5.03% upside from current levels. In a report released yesterday, Robert W. Baird also reiterated a Hold rating on the stock with a $14.00 price target.
The company has a one-year high of $18.86 and a one-year low of $9.50. Currently, Rivian Automotive has an average volume of 32.24M.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Goldman Sachs Sticks to Its Buy Rating for Publicis Groupe (0FQI)
Goldman Sachs analyst Lisa Yang maintained a Buy rating on Publicis Groupe (0FQI – Research Report) yesterday and set a price target of €106.00. The company's shares closed yesterday at €95.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Yang covers the Communication Services sector, focusing on stocks such as ITV plc, WPP, and Prosus. According to TipRanks, Yang has an average return of 8.5% and a 59.36% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Publicis Groupe with a €112.20 average price target, implying a 18.11% upside from current levels. In a report released on June 25, Barclays also maintained a Buy rating on the stock with a €115.00 price target. Based on Publicis Groupe's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €8.38 billion and a net profit of €885 million. In comparison, last year the company earned a revenue of €7.7 billion and had a net profit of €689 million
Business Insider
2 hours ago
- Business Insider
Maxim Group Reaffirms Their Hold Rating on Aethlon Medical (AEMD)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Aethlon Medical (AEMD – Research Report). The company's shares closed yesterday at $1.25. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Vendetti covers the Healthcare sector, focusing on stocks such as Dermata Therapeutics, bioAffinity Technologies, Inc., and Helius Medical Technologies. According to TipRanks, Vendetti has an average return of -27.0% and a 23.28% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Aethlon Medical.
Business Insider
2 hours ago
- Business Insider
Goldman Sachs Sticks to Its Buy Rating for Philogen SpA (78Q)
In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Buy rating on Philogen SpA (78Q – Research Report), with a price target of €29.00. The company's shares closed yesterday at €23.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Sharma is an analyst with an average return of -6.4% and a 29.58% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and AstraZeneca. Currently, the analyst consensus on Philogen SpA is a Moderate Buy with an average price target of €32.00, implying a 39.13% upside from current levels. In a report released on June 25, Stifel Nicolaus also maintained a Buy rating on the stock with a €31.00 price target. The company has a one-year high of €28.00 and a one-year low of €16.10. Currently, Philogen SpA has an average volume of 165.
